ClinicalTrials.gg
CompletedNCT00192335Updated Nov 27, 2007

Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants

A Phase 3 interventional study of CAIV-T and CAIVT in Healthy, sponsored by MedImmune LLC. Completed at 3 sites in United States. Open to participants aged 5 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2007-11-27.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
890
Allocation
Randomized
Ages
5 Years to 49 Years
Sex
All
01

Study summary

  • Primary objective is to demonstrate equivalent immunogeniticity of CAIV-T and FluMist
  • Secondary objective of this study is to assess the safety and tolerability of CAIV-T compared to FluMist
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.

First submitted before MedImmune LLC became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 5 through 49 years (not yet reached their 50th birthday);
  • In general good health;
  • Individual or parent/guardian available by telephone;
  • Ability of the participant or parent/guardian to understand and comply with the requirements of the protocol; and
  • Written and HIPAA authorization obtained from the participant's parent or legal guardian or written informed consent and HIPAA authorization obtained from the participant.

Exclusion criteria

Exclusion Criteria:

  • History of to any component of FluMist or CAIV-T, including egg or egg products;
  • History of hypersensitivity to gentamicin;
  • Any known condition or immune deficiency disease (including infection), or ongoing receipt of any immunosuppressive therapy;
  • Household contact who is immunocompromised (participants should also avoid close contact with other immunocompromised individuals for at least 21 days);
  • History of chronic underlying medical conditions such as chronic disorders of the cardiovascular and pulmonary systems, chronic metabolic diseases (including diabetes), renal dysfunction, or hemoglobinopathies;
  • History of Guillain-Barré syndrome;
  • History of asthma or reactive airways disease;
  • For children age 5 through 8 years, receipt of prior influenza vaccination;
  • Acute febrile (>100.0°F oral) and/or respiratory illness within the 72 hours prior to enrollment;
  • For participants under the age of 18, use of aspirin or aspirin containing products in the 30 days prior to enrollment or anticipated use during the study;
  • Administration of any within 30 days prior to enrollment or if receipt of another live vaccine is expected within 30 days of the vaccination in this study;
  • Administration of any inactivated vaccine within two weeks prior to enrollment or if receipt of another inactivated vaccine is expected within two weeks of the vaccination in this study;
  • Pregnancy or, in biologically capable women (e.g., menses within the last year), not willing to agree to acceptable for 90 days after enrolling into the study (for those biologically capable, a urine pregnancy test must be performed on the day of vaccination with a negative result);
  • Breastfeeding or lactating women;
  • Participation in another trial or administration of any investigational drug within 30 days prior to enrollment or during this study;
  • Receipt of any blood product within 90 days prior to vaccination or expected receipt within the study duration;
  • Employees of the research center, any individuals involved with the conduct of the study, or any family member of such individuals; and
  • Any condition that in the opinion of the investigator would interfere with the interpretation or evaluation of the vaccine.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
890 participants (actual)

Study arms

  • Active comparator
    1

    CAIVT-The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).

    Biological: CAIV-T · Biological: CAIVT

  • Active comparator
    2

    FluMist- The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).

    Biological: FluMist

Interventions

  • BiologicalCAIV-T
  • BiologicalCAIVT

    The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).

  • BiologicalFluMist

    The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).

06

What researchers measure

Primary outcomes

  1. - Among participants 5 through 8 years of age regardless of baseline serostatus who receive two doses, the post-dose two strain-specific geometric mean titers (GMTs) for serum HAI in the CAIV-T group are within 2-fold of those in the FluMist group

    Time frame: greater than 28-days post dose

Secondary outcomes

  1. The proportion of participants experiencing each of the reactogenicity events by dose.

    Time frame: Within 28 days of vaccination

07

Study locations

3 sites
  • Heart of America Research Institute
    Shawnee Mission, Kansas 66216, United States
  • Kentucky Pediatric/Adult Research, Inc.
    Bardstown, Kentucky 40004, United States
  • R/D Clinical Research, Inc.
    Lake Jackson, Texas 77566, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Jul 2004
CompletionActual
Feb 2005
Last update
Nov 27, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00192335
Lead sponsor
MedImmune LLC
First posted
Sep 19, 2005
Start date
Jul 2004
Completion
Feb 2005
Last update
Nov 27, 2007

Study contacts

Luis Angles, MD
principal investigator · Heart of America Research Institute
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FluMist

Start the discussion